Yes, bladder cancer is treatable, and outcomes depend on stage and type

Bladder cancer is treatable at every stage, though the specific treatment and likelihood of long-term survival vary significantly based on how far the cancer has spread and what type of cells it started in. Most bladder cancers are caught early, when they are confined to the inner lining of the bladder—a stage where treatment is most effective. Even advanced cases have treatment options that can extend life and manage symptoms.

The key factor in outcomes is stage: whether the cancer is still in the bladder lining (non-muscle-invasive), has grown into the muscle layer (muscle-invasive), or has spread beyond the bladder. A second factor is grade, which describes how abnormal the cancer cells look under a microscope. Lower-grade cancers tend to grow more slowly and respond better to treatment.

Key Takeaways

  • About 75 percent of bladder cancers are caught before they invade the muscle layer, a stage where treatment success rates are high.
  • Non-muscle-invasive bladder cancer is typically treated with transurethral resection (removing the tumor through the urethra) followed by medication placed directly in the bladder.
  • Muscle-invasive bladder cancer usually requires either chemotherapy plus radiation or surgical removal of the bladder, depending on the person's health and preferences.
  • Newer immunotherapy drugs have improved outcomes for advanced bladder cancer and are now used earlier in treatment for some patients.
  • Recurrence is common with non-muscle-invasive cancer, so ongoing monitoring with cystoscopy (a camera inserted through the urethra) is standard.

How non-muscle-invasive bladder cancer is treated

When bladder cancer has not grown into the muscle layer, the standard first step is transurethral resection of bladder tumor (TURBT). A surgeon passes a thin instrument called a resectoscope through the urethra and removes the visible tumor. This is done under anesthesia and does not require cutting into the abdomen. The removed tissue is examined to confirm the cancer type and stage.

After TURBT, most patients receive medication placed directly into the bladder to reduce the risk of recurrence. The most common is bacillus Calmette-Guérin (BCG), a live weakened bacteria that triggers the immune system to attack remaining cancer cells. BCG is instilled through a catheter once a week for six weeks, then repeated at intervals for up to three years. Some patients receive mitomycin C, a chemotherapy drug, instead of or in addition to BCG.

Because non-muscle-invasive bladder cancer often comes back, patients need regular follow-up cystoscopies—typically every three months for the first two years, then less frequently if no new tumors appear. This monitoring is essential because early detection of recurrence improves treatment outcomes.

Treatment for muscle-invasive bladder cancer

When cancer has grown into the muscle layer, treatment is more intensive. The two main approaches are bladder-preserving chemotherapy and radiation or radical cystectomy (surgical removal of the bladder).

Chemotherapy plus radiation is offered to patients who want to keep their bladder. The chemotherapy drug most commonly used is cisplatin, given intravenously in cycles over several weeks while the patient also receives daily radiation to the bladder. This combination aims to kill cancer cells while preserving bladder function. Success depends on the tumor's response; if imaging shows the cancer has not shrunk adequately, surgery may be recommended.

Radical cystectomy removes the bladder, prostate (in men), and surrounding lymph nodes. Surgeons then create a new way for urine to leave the body—either a neobladder (a pouch made from part of the small intestine that functions like a bladder) or a urostomy (an opening in the abdomen where urine drains into an external pouch). Recovery takes several weeks, and patients need time to adjust to the new urinary system. Some surgeons now use robotic assistance to perform this surgery, which may reduce recovery time.

Immunotherapy and newer drug options

In recent years, immunotherapy drugs have changed treatment for advanced bladder cancer. These drugs—such as atezolizumab, nivolumab, and pembrolizumab—work by releasing the immune system's brakes on cancer cells, allowing the body's own defenses to attack the tumor. They are now used for patients whose cancer has spread beyond the bladder or who cannot tolerate chemotherapy.

Immunotherapy is also being tested earlier in treatment, before surgery or alongside chemotherapy, to see if it improves outcomes for muscle-invasive cancer. Some patients receive immunotherapy after surgery if their cancer was high-risk. Response rates vary; some patients see their tumors shrink significantly, while others do not respond. Blood tests and imaging help doctors determine whether the drug is working.

Other newer drugs target specific genetic mutations in bladder cancer cells. These targeted therapies are used when tumors have particular mutations—for example, FGFR mutations or BRCA mutations. Genetic testing of the tumor can identify whether a patient is a candidate for these drugs.

Survival rates and long-term outcomes

Survival depends heavily on stage. For non-muscle-invasive cancer confined to the bladder lining, the five-year survival rate is around 95 percent. For muscle-invasive cancer that has not spread beyond the bladder, five-year survival is approximately 50 to 60 percent. For cancer that has spread to distant organs, survival rates are lower, though newer treatments are improving these numbers.

These statistics represent averages across all patients and do not predict any individual's outcome. Factors that influence prognosis include the person's age, overall health, whether the cancer is high-grade or low-grade, and how well the tumor responds to initial treatment. Some patients with advanced cancer live for years with treatment, while others progress more quickly.

Many bladder cancer survivors live long, healthy lives after treatment. However, non-muscle-invasive cancer has a high recurrence rate—up to 50 percent of patients will develop a new tumor in the bladder within five years. This is why lifelong monitoring is standard, even for early-stage cases.

Side effects and quality of life during treatment

TURBT is minimally invasive and has few serious side effects, though some patients experience temporary blood in the urine or mild discomfort during urination for a few days after the procedure.

BCG instillation causes irritative symptoms in the bladder—urgency, frequency, and burning during urination—in most patients. These symptoms usually resolve within a few hours to a day after each treatment. Rarely, BCG can cause a systemic infection, which is treated with antibiotics.

Chemotherapy and radiation for muscle-invasive cancer cause more significant side effects: nausea, fatigue, hair loss, and increased infection risk with chemotherapy; and bladder irritation, bowel changes, and fatigue with radiation. Immunotherapy can cause fatigue and, less commonly, autoimmune reactions where the drug triggers the immune system to attack the body's own tissues. Most side effects are manageable with supportive care, and many resolve after treatment ends.

Radical cystectomy requires major surgery recovery, typically four to six weeks before returning to normal activity. Patients need time to learn to manage their new urinary system, whether that is a neobladder or urostomy. Many patients report good quality of life after adjustment, though sexual function may be affected.

Clinical trials and emerging treatments

Bladder cancer research is active, with ongoing trials testing combinations of immunotherapy with chemotherapy, new targeted drugs, and approaches to preserve the bladder in muscle-invasive cases. Some trials are exploring whether certain patients can avoid surgery by using chemotherapy, radiation, and immunotherapy together.

If standard treatment has not worked or a patient wants to explore additional options, clinical trials may be available. The National Cancer Institute maintains a searchable database of trials at clinicaltrials.gov. Talking with an oncologist about whether a trial might be appropriate is a reasonable step, especially for advanced cancer.

Frequently Asked Questions

Can bladder cancer come back after treatment?

Yes, recurrence is common, particularly with non-muscle-invasive cancer. About half of patients will develop a new tumor in the bladder within five years. This is why regular cystoscopy screening is standard. Recurrence does not mean the original treatment failed—it reflects the nature of bladder cancer and the need for ongoing monitoring.

What happens if chemotherapy or radiation does not work?

If the tumor does not shrink after chemotherapy and radiation, surgery to remove the bladder is typically recommended. If cancer returns after surgery or spreads to other organs, immunotherapy or targeted drugs may be offered, depending on the tumor's characteristics and the patient's health.

Is it possible to keep your bladder with muscle-invasive cancer?

Yes, chemotherapy plus radiation is an option for some patients with muscle-invasive cancer who want to preserve bladder function. Success depends on how well the tumor responds to treatment. If imaging shows inadequate response, surgery is usually recommended. Some patients choose surgery upfront because it offers the most definitive treatment.

How long does bladder cancer treatment take?

TURBT is a single procedure. BCG instillation is typically six weeks of weekly treatments, then maintenance doses over one to three years. Chemotherapy and radiation for muscle-invasive cancer usually takes five to six weeks. Surgery and recovery takes several weeks. After initial treatment, monitoring continues indefinitely for non-muscle-invasive cancer and for several years after surgery for muscle-invasive cancer.

Are there side effects that last after treatment ends?

Most acute side effects from chemotherapy and radiation resolve within weeks to months. However, some patients experience long-term bladder irritation, bowel changes, or sexual dysfunction after radiation. Patients who have surgery to remove the bladder need permanent adjustment to their urinary system. Discussing long-term side effects with your oncologist before treatment begins helps you prepare.